US EditionImmunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors
Immunome will present topline Phase 3 RINGSIDE trial data on varegacestat for progressing desmoid tumors during a live webcast with Q&A session.
- Immunome, Inc. announced in a Dec 14, 2025 press release from Bothell, Wash. that it will host a webcast and call on Monday, December 15, 2025 to disclose topline Phase 3 RINGSIDE trial results for varegacestat in patients with progressing desmoid tumors.
- As a clinical-stage oncology company, Immunome, Inc. scheduled the webcast to present topline trial data with presentation slides and a live Q&A via conference call; the webcast is listen-only.
- The live webcast was listen-only, with a live question-and-answer session on the conference call, and the event will remain archived on the Immunome website for 90 days.
- Investor and media contacts were listed for questions and follow-up, including Max Rosett, Chief Financial Officer, Immunome, and Nicole Foderaro, media contact, Real Chemistry; the live webcast and presentation slides are accessible via investors.immunome.com/events.
- With a broader pipeline, Immunome also noted leadership experienced in antibody-drug conjugates and programs including IM-1021, clinical-stage ROR1 ADC, and IM-3050, FAP-targeted radiotherapy with recently received IND clearance.
10 Articles
10 Articles
Why Immunome Stock Surged Today
Key PointsA phase 3 study of varegacestat met its primary endpoint.The drug candidate could reduce the risk of disease progression or death in people with desmoid tumors by 84%.10 stocks we like better than Immunome › Shares of Immunome (NASDAQ: IMNM) jumped over 15% on Monday after the biotech company announced positive clinical results for varegacestat, an investigational treatment for patients with progressing desmoid tumors. Image source: Ge…
The Bakersfield Californian
Immunome Announces Positive Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors
BOTHELL, Wash.--(BUSINESS WIRE)--Dec 15, 2025-
Immunome (IMNM) Stock Surges After Positive Phase 3 Varegacestat Data: Latest News, Analyst Forecasts, and What Comes Next (Dec. 15, 2025)
December 15, 2025 — Immunome, Inc. (NASDAQ: IMNM) is having the kind of biotech day that traders circle in red ink: a major clinical trial win, a sharp move in the share price, and a fast-rising debate over what “best-in-class” might be worth if regulators agree. The catalyst is Immunome’s positive topline Phase 3 RINGSIDE results for varegacestat (formerly AL102) in progressing desmoid tumors—a rare, non-metastatic but often aggressive disease …
Coverage Details
Bias Distribution
- 60% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
